

# ABNORMAL BRAIN SCANS: CONTRIBUTION OF BLOOD RADIOACTIVITY TO IMAGE

Claude Nahmias, Colin E. Webber, Mohammed Banna, and Edmund S. Garnett

*McMaster University Medical Center, Hamilton, Ontario, Canada*

***Images obtained with  $^{99m}\text{Tc}$ -labeled red blood cells were compared with  $^{99m}\text{Tc}$ -pertechnetate scans in 26 patients with primary and secondary brain tumors, intracerebral infarcts, and hemorrhage. The results indicated that the contribution of blood pool radioactivity to a positive brain scan was minor.***

An intracerebral lesion may be demonstrated by brain scanning if it contains more radioisotope than the surrounding brain tissue. The relative contributions of vascular and extravascular radioactivity to the image are not known. The purpose of this study was to determine how often radioisotope confined to the blood compartment made a major contribution to the positive scan.

## MATERIALS AND METHODS

Twenty-six patients were studied. Every patient had an abnormal  $^{99m}\text{Tc}$ -pertechnetate scan and in every case histologic proof of the lesion that caused the abnormal brain scan was obtained (Table 1). Patients were divided into four groups on the basis of the histology of their lesion.

A brain scan was started 10 min after an intravenous injection of 10 mCi  $^{99m}\text{Tc}$ -pertechnetate; 400 mg  $\text{KClO}_4$  was given orally 30 min before the injection.

A labeled red cell brain scan was started 10 min after 16 ml of the patient's own blood labeled with 10 mCi  $^{99m}\text{Tc}$  had been reinjected. The red cells were labeled according to the procedure of Eckelman, et al (1). One hour after the injection of  $^{99m}\text{Tc}$ -labeled red cells, a blood sample was taken to determine the proportion of  $^{99m}\text{Tc}$  bound to red cells.

All of the scans were taken on an Ohio-Nuclear Duo 5 scanner.

The time interval between a pertechnetate and a

red cell scan ranged from 1 to 13 days with a mean of 3.9 days.

Both pertechnetate and labeled red cell scans were set up by assuming that the maximum counting rate from the patient's head would be obtained from the superior sagittal sinus. However, if the lesion could not be seen on the red cell scan, the study was repeated assuming that the maximum counting rate would be that obtained from the lesion itself. This was possible because the position of the lesion was always defined by the positive pertechnetate scan.

## RESULTS

Typical scans are shown in Figs. 1 and 2. Figure 1 shows a meningioma that was detected on both scans; Fig. 2 shows an astrocytoma (Grade III) that was not detected on the red cell scan. It will be noted that the meningioma appears to be appreciably smaller on the red cell scan compared with the pertechnetate scan. This was characteristic of all of the lesions detected on the red cell scan. When a lesion could not be seen on a labeled red cell scan set up on the sagittal sinus, it was never possible to see it on a repeat scan set up on the lesion itself.

The red cell scan was abnormal in four of the seven patients with glioma, in two of the five patients with metastases from the bronchus, in five of the six patients with meningioma, and in four of the eight patients with cerebrovascular accidents.

One hour after the reinjection of  $^{99m}\text{Tc}$ -labeled red blood cells, 92–97% of the circulating activity remained bound to the red cells.

## DISCUSSION

During a red cell brain scan all of the circulating


Received Aug. 29, 1974; revision accepted Jan. 22, 1975.

For reprints contact: E. Stephen Garnett, Dept. of Nuclear Medicine, McMaster University Medical Centre, 1200 Main St. W., Hamilton, Ontario, Canada.


**TABLE 1. PATHOLOGY AND RESULTS OF ANGIOGRAPHY AND <sup>99m</sup>Tc-RED CELL SCAN**

Lesion	Pathology		Angiography*	Lesion seen on red cell scan
		Histologic comment		
Astrocytoma III		Endothelial proliferation and necrosis	++	No
Astrocytoma III		Increased vascularity with endothelial proliferation and necrosis	+	No
Astrocytoma III		Endothelial proliferation and necrosis	0	Yes
Astrocytoma III		Endothelial proliferation and necrosis	++	Yes
Cerebellar astrocytoma		Endothelial proliferation and necrosis	0	No
Glioma		Necrosis	0	Yes
Oligodendroglioma		Marked endothelial proliferation	0	Yes
Metastasis from bronchus		Adenocarcinoma		No
Metastasis from bronchus		Poorly differentiated squamous		Yes
Metastasis from bronchus		Necrosis with cysts	0	No
Metastasis from bronchus		Well-differentiated squamous		No
Metastasis from bronchus		Anaplastic	0	Yes
Meningioma		Typical vascular meningioma	++	Yes
Meningioma		Typical vascular meningioma		Yes
Meningioma		Numerous small vessels throughout tumor	0	Yes
Meningioma		Moderately vascular with necrosis	++	Yes
Meningioma		Extensive capillary network		Yes
Meningioma		Numerous psammoma bodies		No
Intracerebral infarct		Necrotic brain tissue		No
Intracerebral infarct		Necrotic brain tissue	0	Yes
Intracerebral infarct		Necrotic brain tissue		No
Intracerebral infarct		Necrotic brain tissue	+	Yes
Intracerebral hemorrhage		Blood clot	0	No
Intracerebral hemorrhage		Blood clot	0	No
Subarachnoid hemorrhage		Blood clot	0	Yes
Subdural hematoma		Blood clot	0	Yes

\* Vascularity in area of lesion as determined by angiography: 0, avascular; +, vascular; ++, very vascular.



**FIG. 1.** (A) A <sup>99m</sup>TcO<sub>4</sub> scan showing parasagittal meningioma and (B) <sup>99m</sup>Tc-labeled red blood cell scan of same patient.



**FIG. 2.** (A) A <sup>99m</sup>TcO<sub>4</sub> scan showing right parietal astrocytoma (Grade III) and (B) <sup>99m</sup>Tc-labeled red blood cell scan of same patient.

radioactivity was bound to the red cells. This agrees with Korubin, et al (2) who found little difference between the volume of distribution of pertechnetate and chromium-labeled red cells up to 2 hr. Since these tumors showed the characteristic vascular pattern (Table 1), it is therefore not surprising that all but one of the meningiomas could be detected on the red cell scan. The one meningioma that could not be seen on the red cell scan was situated in the

posterior fossa and its histology was characterized by psammoma bodies and not increased vascularity.

The salient feature of this study was that only half of the remaining lesions could be detected on the red cell scan. Furthermore, there seemed to be no relation between the results of the red cell scan and the presence or absence of increased vascularity assessed histologically or by angiography (Table 1).

During a red cell scan almost all of the radioactivity

remains in the circulation. During a pertechnetate scan radioactivity is lost rapidly from the vascular compartment so that by the end of a scan less than half of the initial radioactivity remains in the blood (3,4). This means that during a red cell scan the concentration of radioactivity in the blood was at least twice that present during a pertechnetate scan. In spite of this only half of the gliomas, metastases, and cerebrovascular accidents could be demonstrated on the red cell scan. Furthermore, when a lesion was detected on a red cell scan, it was always smaller and less obvious than on the corresponding pertechnetate scan. This difference was seen in all of the lesions irrespective of their histology. Since the red cell and pertechnetate scans were all set up within 10 min of the injection of isotope, only a fraction of this difference can be explained on instrument settings. It therefore seems that radioactivity con-

finied to the blood pool makes a relatively small contribution to a positive pertechnetate brain scan. This supports the hypothesis that, when a lesion is detected on a pertechnetate scan, the bulk of the radioactivity is in the extravascular compartment.

**ACKNOWLEDGMENT**

We thank J. Groves for the histologic studies.

**REFERENCES**

1. ECKELMAN W, RICHARDS P, HAUSER W, et al: Technetium-labeled red blood cells. *J Nucl Med* 12: 22-24, 1971
2. KORUBIN V, MAISEY MN, MCINTYRE PA: Evaluation of technetium-labeled red cells for determination of red cell volume in man. *J Nucl Med* 13: 760-762, 1972
3. OLDENDORF WH: Distribution of various classes of radiolabeled tracers in plasma, scalp, and brain. *J Nucl Med* 13: 681-685, 1972
4. GARNETT ES: Unpublished data

**GREATER NEW YORK AREA CHAPTER  
THE SOCIETY OF NUCLEAR MEDICINE  
FIRST ANNUAL SCIENTIFIC MEETING**

The Greater New York Area Chapter of the Society of Nuclear Medicine will hold its first annual meeting on November 21-23, 1975, in the Empire Room of the Waldorf Astoria. The program will include scientific sessions, teaching sessions, and commercial exhibits.

A unique approach to be utilized at this meeting will be the format of panel discussions on major subject areas in nuclear medicine. Each panel will be conducted by a group of experts in that specific area, including members of the Chapter and outside speakers. The subjects chosen for this meeting include: Radionuclide Procedures in the Detection of Neoplasms; Radioimmunoassay; Cardiovascular Nuclear Medicine; The Role of Nuclear Medicine in Benign Bone Disease; Trauma; and New Concepts and Developments in the Field of Nuclear Medicine Instrumentation. Members of the New York Chapter are invited to submit original papers for inclusion in any of these panels. Papers are to be submitted by September 15, 1975, to John S. Laughlin, Ph.D., Memorial Sloan-Kettering Cancer Center, 410 East 68th Street, New York, N.Y. 10021.

Formal teaching sessions conducted by invited experts will cover the fields of: Tracer Kinetics, Federal Regulatory Agencies, Computer-Aided Axial Tomography and Brain Scanning, Quality Control, Radiopharmaceuticals, Ultrasound and Nuclear Medicine, Thyroid Therapy and Diagnosis, and Pediatric Nuclear Medicine.

Registration fees for the meeting will be \$15.00 for technicians who are members of the New York Chapter, medical students and house officers with supporting letters; \$25.00 for full members of the New York Chapter and for technicians who are not members of the New York Chapter; \$50.00 for all other individuals.

Members of the New York Chapter will be admitted to the business meeting without charge.

For further information concerning programs and exhibits, contact Society of Nuclear Medicine, 475 Park Avenue South, New York, N.Y. 10016.